Superlatus, Inc., a food
technology and distribution company that recently merged with a
subsidiary of pharmaceutical exchange platform provider
TRxADE HEALTH, Inc. (Nasdaq:
MEDS), today announced it plans to enter the worldwide pet
foods market, specializing in plant-based, high-protein foods and
snacks.
Superlatus will launch the expansion with
assorted flavors of baked plant-based treats, then intends to
follow with a full offering of veterinarian formulated,
plant-based, high-protein full meal offerings. All products will
feature reduced calorie and saturated fat content compared to
traditional animal-based pet meals and treats and will utilize
plant-based ingredients from strategic supply partners.
The company is currently in discussion with
several major national pet food chains to participate as a
launch partner for the products, said Superlatus.
All the new treat offerings will utilize an
advanced food extrusion technology from Sapientia Technology, LLC,
a wholly owned subsidiary of Superlatus. This technology, developed
by well-known food scientist Dr. Gino Bortone, enables Superlatus
to create dense, protein rich, plant-based dog treats.
“We are excited to enter this market,” stated
Superlatus CEO Tim Alford. “According to a broad array of
established data sources, the plant-based segment of the pet food
industry is growing significantly faster than the traditional
animal-based segment.”
One such source, Future Market Insights
(FMI), recently announced that, in 2023, the vegan dog food
market was estimated to be worth $13.58 billion and is anticipated
to register a CAGR of 7 percent for the next 10 years,
reaching a value of $ 26.35 billion by 2033.
In contrast, reported FMI, the conventional,
animal-based dog food market, which has a current value of $68.27
billion, is anticipated to expand with a CAGR of only 4.35 percent
to 2033. This slower rate of projected growth, added FMI, is
attributable primarily to both widespread consumer awareness of the
health advantages of vegan pet foods as well as the increased
numbers of online sales channels available for such foods.
“As a company with a core mission to create a
healthier and more sustainable future for our planet, we are
extremely proud to offer consumers these better-for-your-pet food
products,” continued Mr. Alford. “We believe they will rank among
the healthiest and most delicious products our pets can eat.
“We anticipate the initial line of vegan pet
treats will likely be available by Q1 2024 with the vegan full meal
offerings hitting the market by later in 2024.”
About Superlatus,
Inc.
Superlatus is a diversified food technology
company with distribution capabilities. We scale food innovation
and transformational change to our food systems to optimize food
security and population health via innovative CPG products,
agritech, foodtech, plant-based proteins and alt-proteins. We
provide industry-leading processing and forming technologies that
create high nutrition, high taste, and textured foods. Our
management team consists of world-class food executives with an
unparalleled understanding of technology and taste. For more
information on Superlatus, please visit Superlatus’ website
at https://www.superlatusfoods.com.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ: MEDS) is a health
services IT company focused on digitalizing the retail pharmacy
experience by optimizing drug procurement, the prescription journey
and patient engagement in the U.S. TRxADE HEALTH ( NASDAQ: MEDS)
plans to exit its legacy businesses and focus on the Superlatus
foods business after its next special meeting of shareholders. For
more information on TRxADE HEALTH, please visit the Company’s IR
website at investors.trxadegroup.com.
Forward-Looking Statements
This press release contains certain statements
that may be deemed to be “forward-looking statements” within the
federal securities laws, including the safe harbor provisions under
the Private Securities Litigation Reform Act of 1995. Statements
that are not historical are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements relate to future events or our future performance or
future financial condition. These forward-looking statements are
not historical facts, but rather are based on current expectations,
estimates and projections about our company, our industry, our
beliefs and our assumptions. Such forward-looking statements
include, but are not limited to, statements regarding our or our
management team’s expectations, hopes, beliefs, intentions or
strategies regarding the future. In addition, any statements that
refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements. In some cases, you can
identify forward-looking statements by the following words:
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “ongoing,” “plan,” “potential,” “predict,”
“project,” “should,” or the negative of these terms or other
similar expressions, but the absence of these words does not mean
that a statement is not forward-looking. Forward-looking statements
are subject to a number of risks and uncertainties (some of which
are beyond our control) that may cause actual results or
performance to be materially different from those expressed or
implied by such forward-looking statements. Accordingly, readers
should not place undue reliance on any forward-looking statements.
These risks include risks relating to agreements with third
parties; our ability to raise funding in the future, as needed, and
the terms of such funding, including potential dilution caused
thereby; our ability to continue as a going concern; security
interests under certain of our credit arrangements; our ability to
maintain the listing of our common stock on the Nasdaq Capital
Market; claims relating to alleged violations of intellectual
property rights of others; risks that our food products will not
achieve expected market acceptance; the outcome of any current
legal proceedings or future legal proceedings that may be
instituted against the parties or others; and those risks detailed
in TRxADE’s most recent Annual Report on Form 10-K and subsequent
reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made.
The TRxADE undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date, except as
otherwise provided by law.
Investor Contact:Skyline Corporate
Communications Group, LLCScott Powell, PresidentOne Rockefeller
Plaza, 11th FloorNew York, NY 10020Office: (646)
893-5835Email: info@skylineccg.com
TRxADE Health (NASDAQ:MEDS)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
TRxADE Health (NASDAQ:MEDS)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024